Reversible amiodarone-induced lung disease: HRCT findings

被引:20
|
作者
Vernhet, H [1 ]
Bousquet, C [1 ]
Durand, G [1 ]
Giron, J [1 ]
Senac, JP [1 ]
机构
[1] Hop Arnaud Villneuve, Dept Thorac & Cardiovasc Radiol, F-34295 Montpellier, France
关键词
high-resolution CT; lungs; infiltrative lung diseases; drug effects; amiodarone;
D O I
10.1007/s003300000809
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The aim of this study was to describe thoracic high-resolution computed tomography (HRCT) findings of reversible amiodarone-induced lung disease (AILD). The thoracic HRCT of 20 symptomatic patients who were considered as having reversible AILD by the medical staff of our institution were retrospectively reviewed. The patient-selection criteria used were the development of new respiratory symptoms while receiving amiodarone, the exclusion of other respiratory and cardiac diseases, and the decrease of both respiratory symptoms and radiological abnormalities after cessation of amiodarone and corticotherapy. The CT data recorded were those usually sought infiltrative lung diseases. The radiological findings using chest film (n = 20) and HRCT (n = 4) follow-up was noted. All patients had ground-glass opacities, associated with consolidations (n = 4), thin intralobular reticulations (n = 5), or both (n = 11), with a subpleural (n = 18) or central (n = 2) location. Eight patients had high-density areas and 13 had pleural thickening (n = 13). Bronchial abnormalities included dilation (n = 16) and wall thickening (n = 19). After therapeutic management, the radiological follow-up showed complete (n = 17) or incomplete (n = 3) improvement. Ground-glass opacities associated with thin intralobular reticulations and/or subpleural consolidations and bronchial abnormalities are common HRCT findings in reversible AILD.
引用
收藏
页码:1697 / 1703
页数:7
相关论文
共 50 条
  • [41] Amiodarone-induced hepatotoxicity
    Nagata, Takahiro
    Takata, Kazuhide
    Shakado, Satoshi
    Hirai, Fumihito
    [J]. BMJ CASE REPORTS, 2023, 16 (11)
  • [42] AMIODARONE-INDUCED THROMBOCYTOPATHY
    BERREBI, A
    SHTALRID, M
    VORST, EJ
    [J]. ACTA HAEMATOLOGICA, 1983, 70 (01) : 68 - 69
  • [43] Amiodarone-induced thyrotoxicosis
    Anfinsen, Ole-Gunnar
    Lima, Kari
    [J]. TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2021, 141 (16) : 1528 - 1532
  • [44] AMIODARONE-INDUCED THROMBOCYTOPENIA
    WEINBERGER, I
    ROTENBERG, Z
    FUCHS, J
    BENSASSON, E
    AGMON, J
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1987, 147 (04) : 735 - 736
  • [45] AMIODARONE-INDUCED PNEUMONOPATHY
    BRAMBILLA, C
    CHAVEZ, L
    PIOT, M
    RIGAUD, D
    PARAMELLE, B
    [J]. PRESSE MEDICALE, 1983, 12 (19): : 1236 - 1236
  • [46] AMIODARONE-INDUCED CHOLESTASIS
    TILZ, GP
    LIEBIG, E
    PRISTAUTZ, H
    [J]. MEDIZINISCHE WELT, 1989, 40 (36): : 985 - 986
  • [47] Amiodarone-induced ceruloderma
    Farhat-Sabet, Ardalon M.
    Fentanes, Emilio
    [J]. EUROPEAN HEART JOURNAL-CASE REPORTS, 2018, 2 (01)
  • [48] Amiodarone-induced thyrotoxicosis
    Chen, Peng-Sheng
    [J]. HEART RHYTHM, 2007, 4 (09) : 1247 - 1247
  • [49] Amiodarone-induced thyrotoxicosis
    Gama, R
    [J]. HOSPITAL MEDICINE, 2002, 63 (12): : 753 - 753
  • [50] Amiodarone-induced thyrotoxicosis
    Piga, M.
    Serra, A.
    Boi, F.
    Tanda, M. L.
    Martinos, E.
    Mariotti, S.
    [J]. MINERVA ENDOCRINOLOGICA, 2008, 33 (03) : 213 - 228